 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > TAP Pharmaceutical Products Inc.
 |
TAP Pharmaceutical Products Inc. |
 |
 |
 |
PROFILE |
 |
TAP Pharmaceutical Products (formerly TAP Holdings) taps into the drug industry's hottest trends. A 50/50 joint venture between Abbott Laboratories and Japan's Takeda Chemical Industries, the firm focuses on developing and marketing drugs in the US and Canada. Its focus areas include cancer, gastroenterology, gynecology, and urology. TAP's product Lupron is used to treat prostate cancer and endometriosis. TAP also markets gastric acid inhibitor Prevacid with parent Abbott. Among its drug candidates is fast-acting (15 minutes or less) erectile dysfunction treatment Uprima. Facing questions about Uprima's efficacy and safety, TAP has withdrawn its FDA application; the drug has won approval in Europe.
COMPETITION |
 |
AstraZeneca PLC (AZN)
PRAECIS PHARMACEUTICALS INCORPORATED (PRCS)
Pfizer Inc (PFE)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 2,927.50
1-Yr. Sales Growth: 41.9%
Employees: 2,000
Revenue per employee: $1,463,750.00
KEY PEOPLE |
 |
H. Thomas Watkins
CEO
Kevin Dolan
CFO
CONTACT INFO |
 |
675 North Field Dr.
Lake Forest, IL 60045
US
Phone: -
Fax: 800-830-6936
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |